Zolgensma gene therapy liver damage usually resolves in months
Liver damage may occur as a side effect of the spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi), but it usually resolves within a few months of treatment, a study showed. The researchers also found that simultaneous treatment with Zolgensma and Spinraza (nusinersen) does not seem to…